Alan James Munro (born 19 February 1937) is a British immunologist and entrepreneur who served as the Master of Christ's College, Cambridge (1995–2002).
He spent sabbatical years at the Salk Institute, La Jolla, USA (1965–66) and University of Leiden, the Netherlands (1976–77).
He was instrumental in the early investigation of the Campath series of antibodies, which eventually resulted in the cancer treatment, alemtuzumab.
[1] He left the university in 1989 to co-found the highly successful Cambridge-based biotechnology company Immunology Ltd, later renamed Cantab Pharmaceuticals plc (now part of Celtic Pharma), specialising in therapeutic vaccines and immunotherapy, and he acted as its scientific director until 1995.
[1] As of 2006, Munro chairs the New Agents Committee of Cancer Research UK[5] and holds non-executive directorships of Blackwell Publishing Ltd and Paradigm Therapeutics.